They raised full-year guidance while their supposed 'AI growth engine' in Electronics collapsed 30% organically.
Thesis: This is a misclassified asset. The market is dumping it as a failed semiconductor play because DS&S tanked 30%, but the actual profit engine—Life Science Process Solutions—is a 'Beat and Raise Machine' growing 11.5% organically. With 90% consumables revenue and book-to-bill >1, the bioprocess leverage is massive. You buy the pharma monopoly today; the semiconductor materials recovery in 2026 is free upside. The 'AI' narrative is currently a trap, but the cash flow from the lab funds the wait for the fab.
Verdict: LONG — Conviction: HIGH
Catalyst: Process Solutions hitting its midterm 10% CAGR target in 2025, two years ahead of schedule, validating the post-destocking recovery.
Key Risk: The 'project pushouts' in Electronics turn into cancellations, revealing the DS&S decline is structural share loss rather than cyclical timing.
The Tell: Kai Beckmann admitted the 'unusual amount of large project business' in Electronics has 'peaked' and is 'going back to normal levels.' He effectively confessed the previous growth spike was non-recurring construction, not structural demand.
Friction Level: MODERATE_FRICTION — The Street sees a broken semiconductor story in the 30% DS&S drop; the Smart Money sees a bioprocess monopoly printing cash with a free call option on 2026.
Report not found
The report data is no longer available. Please return to the archive.